- Ipilimumab plus nivolumab demonstrated antitumor activity with acceptable toxicity in patients with metastatic renal cell carcinoma (RCC) who had prior treatment with checkpoint inhibition.
Why this matters
- Ipilimumab plus nivolumab may be an effective salvage treatment option.
- Further research is needed, however, to define durability of response and benefit vs risk.
- 45 patients with metastatic RCC (median age, 62 years) who received prior anti-PD-1 pathway-targeted therapy and subsequently received ipilimumab plus nivolumab.
- Outcome: objective response rate, PFS, toxicity.
- 38% of patients had brain metastasis.
- The median time receiving prior immune checkpoint inhibitors was 13 months.
- The median follow-up was 12 months.
- The objective response rate was 20%.
- 20% of patients had partial responses, and 16% had stable disease.
- The median PFS was 4 (range, 0.8-19) months.
- The median duration of response was 7 (range, 2-17) months.
- 64% of patients experienced any grade and 13% had grade 3-4 immune-related adverse events.
- Small retrospective study.